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Background: High-dose IL-2 (HDIL2) is approved for the treatment of metastatic melanoma and renal cell carcinoma,
but its use is limited in part by toxicity related to the development of vascular leak syndrome (VLS). Therefore, an
understanding of the mechanisms that underlie the initiation and progression of HDIL2-induced increases in
endothelial cell (EC) permeability leading to VLS are of clinical importance.
Methods: We established a novel ex vivo approach utilizing primary human pulmonary microvascular ECs to evaluate
EC barrier dysfunction in response to IL-2.
Results: Complementary in vitro studies using exogenous IL-2 and ex vivo studies using serum from patients treated
with IL-2 demonstrate that HDIL2 induces VLS through CD144 (vascular endothelial (VE)-cadherin) redistribution.
Conclusions: These findings provide new insight into how IL-2 induces VLS and identifies VE-cadherin as a potential
target for preventing IL-2-related VLS.
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High-dose IL-2 (HDIL2) is an approved immunotherapy
for patients with metastatic melanoma and renal cell
carcinoma with durable objective responses observed in
17-20% [1,2]. The major toxicity related to HDIL2 treat-
ment is the development of vascular leak syndrome
(VLS) characterized by increased vascular permeability
leading to decreased end-organ perfusion and, in severe
cases, pulmonary and cardiovascular failure [2-5]. The
mechanisms that underlie the development of vascular
leak during HDIL2 therapy are not well understood, but
it has been hypothesized that such mechanisms involve
the direct effects of IL-2 on endothelial cells (ECs) [6-8].
Currently, no clinical strategies are available for the pre-
vention of VLS in HDIL2-treated patients.
Investigation into the pathogenesis of vascular leak
syndrome is complicated by a lack of appropriate animal
or ex vivo models that accurately replicate human endo-
thelial tissue. The goal of this study was to establish an* Correspondence: howard.kaufman@rutgers.edu
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anism of endothelial cell dysfunction during HDIL2
immunotherapy using primary human pulmonary
microvascular ECs. Understanding the causes of vascular
leak syndrome and EC-mediated injury during HDIL2
therapy may help identify novel therapeutic targets to
limit the adverse effects in these patients while maintain-
ing the direct effects on immune cells and, thus, pre-
serve the therapeutic benefit of HDIL2 treatment in
patients with cancer.Methods
Patient sample acquisition
Eight patients with metastatic melanoma or renal cell
carcinoma treated with high-dose bolus IL-2 between
September 2003 and July 2005 were eligible for partici-
pation (Table 1). The clinical protocol was approved by
the Institutional Review Board, and written informed
consent was obtained from all patients prior to the initi-
ation of the study. Patients also met the institutional
standards for high-dose IL-2 administration. High-dose,
bolus IL-2 was administered at 600,000 IU/kg every
8 hrs up to 15 maximum doses or until irreversible. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patient characteristics





1 49 F 11 B.D 54.4 +
2 63 M 10 1.1 123.2 +
3 24 F 8 B.D. 264.3 +
4 49 F 8 B.D. 130.8 +
5 52 M 10 B.D. 878.4 +
6 51 M 7 B.D. 94.6 +
7 70 M 7 B.D. 348.4 -
8 50 M 9 B.D. 226.4 +
B.D: below the limit of detection by ELISA.
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lected prior to the initiation of IL-2 treatment and
within eight hours after the fourth dose of each cycle of
IL-2 therapy. Clinical data were collected on each pa-
tient by chart review and blood pressure less than
90 mmHg systolic was recorded as hypotension.
Quantitation of IL-2 in patient serum using ELISA
IL-2 concentration was measured using an ELISA kit ac-
cording to the manufacturers’ instructions (eBioscience,
San Diego, CA, USA). Briefly, the serum samples were
added to 96 well plates precoated with an anti-IL-2 cap-
ture antibody. After overnight incubation, anti-IL-2 de-
tection antibody conjugated with biotin was added to
the wells for one hour, followed by horse radish peroxid-
ase (HRP)-conjugated avidin for 30 min and HRP sub-
strate for 15 min. The reaction was stopped with 1 N
H2SO4, and absorbance at 450 nm was measured using
an ELISA plate reader. The concentration of the samples
was calculated after constructing a standard curve, and
all samples were analyzed in duplicates.
Endothelial cell cultures
Primary human pulmonary microvascular ECs (Cambrex,
East Rutherford, NJ, USA) were grown on dishes pre-
coated with 4 μg/ml fibronectin in DMEM containing 5%
FBS. In some experiments IL-2 (100 IU/ml), TNF-alpha
(20 ng/ml), or anti-IL-2 antibody (10 μg/ml; clone 5334)
from R&D Systems (Minneapolis, MN, USA) were added
to the culture, as described for specific experiments.
Detection of IL-2 receptor subunits using RT-PCR and flow
cytometry
The expression of IL-2Rα, Rβ, and Rγ by ECs was ex-
amined using RT-PCR. Total RNA was extracted from
ECs using the RNeasy Mini Kit (Qiagen, Valencia, CA,
USA). The first strand cDNA was synthesized using a
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystem, Grand Island, NY, USA). IL-2Rα was de-
tected using a commercially available human IL-2Rαprimer pair according to the manufacturer’s instruc-
tions (R&D Systems). For IL-2Rβ and Rγ, the cDNA
was denatured at 95°C for 10 min before Taq Polymer-
ase was added. This was followed by 40 cycles of de-
naturation at 95°C for 60 sec, annealing at 55°C (IL-2
Rβ) or 59°C (IL-2 Rγ), extension at 72°C for 60 sec, and
final extension for 7 min at 72°C. The sequences of the
primers were as follows: IL-2 Rβ (F:GGCTTTTGG
CTTCATCATCT; R:CTTGTCCCTCTCCAGCACTT);
IL-2Rγ (F:ACGGGAACCCAGGAGACAGG; R:AGCG
GCTCCGAACACGAAAC). The products of amplifica-
tion were separated using a 1.5% agarose gel in 1xTBE
containing 2 μg/ml ethidium bromide and were visual-
ized using UV light. For each PCR reaction, cDNA from
peripheral blood mononuclear cells and cDNA from Refer-
ence RNA (BD Biosciences, San Jose, CA, USA) were used
as a positive control. The quality of the cDNA was con-
firmed using β-actin.
Expression of IL-2 receptor subunits
IL-2 protein expression was examined using flow cytom-
etry. Single cell suspensions of ECs were obtained by
mechanically scraping the cells off the dishes without
trypsinization. Cells were blocked with 2% FBS for
30 min, followed by incubation with anti-IL-2Rα (clone
A251, BD Biosciences), anti-IL-2Rβ (clone Mikβ2, BD
Biosciences), or anti-IL-2Rγ (clone TUGh4, BD Biosci-
ences) for 30 min and washed. Cells incubated with a
control isotype IgG were used to set up gating for flow
cytometry analysis (BD Biosciences). Only viable cells
were gated for expression of IL-2R.
Measurement of dextran fluxes and distribution of CD144
(VE-cadherin)
Dextran fluxes across ECs were evaluated using trans-
well chambers in the absence of hydrostatic or oncotic
pressure gradients. ECs were seeded onto transwell in-
serts (6.5 mm diameter and 0.4 μm pore size) coated
with 4 μg/ml fibronectin. ECs were treated with paired pa-
tient serum (from patient pre- and post-IL-2 treatment
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FITC-conjugated dextran (10 kD) was added to the top
well, and 100 μl aliquots of samples were taken from the
bottom chamber at 4 and 24 hours. Each time after taking
a sample, 100 μl of media was added back to the bottom
chamber. For each time point, the amount of dextran in
all the samples removed was measured using a fluores-
cence plate reader and calculated after constructing a
standard curve. In all the experiments, a linear line was
obtained for up to 24 hr of dextran measurement, and the
slope of this linear line was calculated and referred to as
permeability index (with increased permeability resulting
in a greater slope, and thus greater permeability index).
Distribution and internalization of CD144 (VE-cadherin)
To determine the distribution of CD144 (VE-cadherin)
and F-actin, cells were fixed with 1% paraformaldehyde
and washed with PBS. VE-cadherin was detected using a
mouse anti-human VE-cadherin antibody (Clone 55-
7H1, BD Biosciences) and a fluorescein-conjugated goat
anti-mouse IgG. F-actin was detected using rhodamine-
phalloidin. The images were acquired using a scanning
confocal microscope (BioRad, Hercules, CA, USA).
To evaluate VE-cadherin endocytosis, cell surface VE-































Figure 1 IL-2 induces an increase in EC permeability. A) IL-2 receptor α
cDNA, lane 2: cDNA isolated from peripheral blood mononuclear cells, lane
representative of five experiments with similar results. B) Expression of IL-2
flow cytometry. Specific staining was compared with background staining
with similar results. C) As a positive control, the effect of TNF-α (20 ng/ml)
flux of dextran across ECs 24 hours after treatment. D) ECs were treated wi
across ECs was measured 24 hours after treatment. Data in (C-D) are prese
experiments with similar results, and *p < 0.05 examined using ANOVA.with an anti-human VE-cadherin antibody (10 μg/ml,
clone: BV-6). Unbound antibody was removed by rinsing
cells in ice-cold cell culture medium. The cells were then
transferred to 37°C for 1 hr to initiate internalization of
molecules from the cell surface. Cells were then fixed
with 1% paraformaldehyde and incubated with a
fluorescein-conjugated goat anti-mouse IgG. Images
were acquired using a BioRad scanning confocal micro-
scope. Quantification of images was performed using
imagej64 software (NIH, imagej.nih.gov/ij/download/) as
previously described [9].
Statistical analysis
Data were analyzed using the Student t-test or one-way
ANOVA followed by post-hoc comparisons (LSD or
Bonferroni) using Prism v4.0 software (GraphPad Software,
Inc., La Jolla, CA, USA). A p value less than 0.05 was
considered significant. Data are expressed as the mean
value + SEM.
Results and discussion
The mechanism by which IL-2 therapy leads to EC in-
jury and subsequent VLS is currently unknown. We
established an ex vivo pulmonary microvascular endo-




, β, and γ subunit levels as determined using RT-PCR. Lane 1: reference
s 3–5: cDNA isolated from ECs from three different donors. Data are
receptor α, β, and γ subunits on the surface of ECs as examined using
using an isotype control antibody. Data represent three experiments
or vehicle [PBS] on EC permeability was measured by determining the
th 100 IU/ml IL-2 or without [Vehicle: PBS], and the flux of dextran
nted as mean + S.E.M. (n = 4 in each group), are representative of three
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allowed us to evaluate the flux of a small molecular
weight tracer (FITC-dextran, 10 kD) across human pri-
mary ECs in the absence of a hydrostatic or oncotic
pressure gradient. By setting the hydrostatic and oncotic
pressure gradient constant, this system allows evaluation
of EC barrier ability to restrict diffusion of dextran and
to represent this value as a permeability index. To valid-
ate the model, we first confirmed expression of the tri-
meric IL-2 receptor on microvascular endothelial cells.
We found that ECs expressed high levels of the IL-2Rβ
and γ chains but only low levels of the IL-2Rα chain by
both mRNA (Figure 1A) and protein (Figure 1B) ana-
lysis. This suggests that the pulmonary microvascular
ECs express an intermediate affinity IL-2 receptor, and
verifies previous reports [10].
Next, we determined a clinically relevant dose of IL-2
for in vitro studies by evaluating serum IL-2 concentra-
tions in a cohort of eight patients being treated with
HDIL2 (Table 1). Prior to IL-2 therapy serum IL-2 levels
were undetectable (in seven patients) or low (in one pa-
tient), whereas 48 hours into HDIL2 treatment, the me-
dian serum IL-2 concentration was 178.9 IU/ml (Table 1).
Based on these measurements we utilized a 100 IU/ml
dose for further in vitro assays. We determined the per-

















Figure 2 IL-2 enhances VE-cadherin endocytosis. A) ECs were treated w
presence of a functional blocking anti-IL-2 antibody for 24 hr. VE-cadherin
TNF-α was examined as a control. B) Data from (A) were quantified using ima
(i.e., intracellular intensity in arbitrary units) is shown. Gray line indicates image
IL-2) or 100 IU/ml IL-2 for 24 hrs. Cell surface VE-cadherin was labeled at 4°C t
endocytosis. VE-cadherin was examined using confocal microscopy. Data shocoated with the microvacular ECs, as described in the
Methods. As a positive control, we utilized TNF-α, which
induces EC injury via increased permeability. TNF-α sig-
nificantly increased the permeability index compared to
vehicle alone (5.8 ± 0.5 with TNF-α versus 4.3 ± 0.1 with-
out TNF-α, p < 0.05) (Figure 1C). IL-2 at 100 IU/ml in-
creased the flux of dextran across ECs (mean permeability
index [mpi]: 4.8 ± 0.2 with IL-2 versus 4.2 ± 0.1 without
IL-2 [vehicle], p < 0.05) (Figure 1D). Dextran flux was
similar at 100, 1000, and 10000 IU/ml of IL-2 (Additional
file 1: Figure S1); therefore, remaining experiments were
conducted at 100 IU/ml. These data demonstrate that IL-
2 alone is sufficient to increase the permeability of ECs
and that changes in permeability can be detected using
the transwell flux system.
Changes in the EC cytoskeleton and disruption of
junctional adhesion molecules have been attributed to
redistribution of F-actin and VE-cadherin [11]. To deter-
mine whether such changes are involved in IL-2-
mediated increases in EC permeability, we stained the
ECs for F-actin and CD144 (VE-cadherin) after treat-
ment with 100 IU/ml of IL-2 (Figure 2A). These studies
demonstrated redistribution of VE-cadherin but not
F-actin in the intracellular compartment (Figure 2A,B).
IL-2-induced VE-cadherin intracellular redistribution














































ith Vehicle (PBS without IL-2), 100 IU/ml IL-2, or 100 IU/ml IL-2 in the
and F-actin were examined using confocal microscopy. The effect of
gej64 software (NIH). VE-cadherin and F-actin intracellular redistribution
background intensity. C) ECs were treated with Vehicle (PBS without
o inhibit endocytosis. Cells were then incubated at 37°C for 1 hr to initiate
wn represent two independent experiments.
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resulted in intracellular redistribution of F-actin but not
VE-cadherin (Figure 2A,B), thus demonstrating the spe-
cificity of IL-2 action on VE-cadherin. This suggests that
the action of HDIL2 on VE-cadherin may occur by a
unique mechanism for vascular leak different from that
which occurs in septic shock and supports blockade of
VE-cadherin redistribution as a strategy for preventing
IL-2-induced VLS.
The intracellular accumulation of VE-cadherin may be
due to enhanced VE-cadherin endocytosis, as has been
shown in the context of the vascular endothelial growth
factor-induced increases in EC permeability [12]. There-
fore, to determine whether IL-2-mediated redistribution
was a result of VE-cadherin endocytosis, we labeled cell
surface VE-cadherin (using an antibody that recognizes
an extracellular VE-cadherin epitope) and transferred la-
beled cells to 37°C to initiate endocytosis. Increased
VE-cadherin endocytosis was detected in cells treated
with IL-2 compared to vehicle-treated cells (Figure 2C).
These data suggest that IL-2 results in increased vascular
permeability due to VE-cadherin intracellular redistribu-




























































































Figure 3 Serum IL-2 results in altered CD144 (VE-cadherin) distribution
ECs were treated with paired pre- or post-IL-2 serum, and the rate of dextran
Individual data points and mean values ± S.E.M. are shown in the graph. * p w
cultured with a functional blocking anti-IL-2 antibody or an isotype control Ig
distribution of VE-cadherin and F-actin was examined using confocal microsc
representative of 4 patients tested. C) Data from (B) were quantified using im
(i.e., intracellular intensity in arbitrary units) is shown. Gray line indicates imageTo determine whether the observed in vitro IL-
2-induced changes in VE-cadherin distribution likewise
may occur in vivo, we evaluated VE-cadherin accumula-
tion after culture of ECs with patient serum. First, we con-
firmed that serum from patients treated with HDIL2
significantly increased EC permeability compared with
paired pre-IL-2 therapy serum in seven of eight patients
(mpi: 3.9 ± 0.1 versus 4.5 ± 0.2, respectively, p = 0.006)
representing an approximately 15% overall increase
(Figure 3A). Interestingly, all patients in the trial devel-
oped hypotension except patient 7 (Table 1) whose EC
permeability here did not increase with post-IL-2 therapy
serum. Post-IL-2 serum, but not pre-IL-2 serum, induced
an increase in intracellular VE-cadherin but not F-actin
(Figure 3B,C). This effect was seen in post-IL-2 serum
from several patients across of range of serum IL-2
concentrations (range, 130.8 - 878.4 IU/ml; see Additional
file 2: Figure S2). Further, this intracellular VE-cadherin
increase was abrogated by an anti-IL-2 antibody
(Figure 3B,C). These data suggest that, similar to the effect
of exogenous IL-2 on EC barrier function in vitro, patient
serum high-dose IL-2 also has the capability to increase
EC permeability through VE-cadherin redistribution.VE-cadherin F-actin Overlay
in the EC cytoskeleton. A) Primary human pulmonary microvascular
flux across an EC monolayer was measured after 24 hr of incubation.
as determined using paired t-test. B) Pre- and post-IL-2 serum was
G for 30 minutes and then used to treat ECs for 24 hr. The effect on the
opy. An image in which Patient 5 serum was used is shown and is
agej64 software (NIH). VE-cadherin and F-actin intracellular redistribution
background intensity. Data represent two independent experiments.
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lar leak occurs, at least in part, due to disruption of the
EC barrier upon engagement of an intermediate affinity
EC IL-2R and is associated with increased VE-cadherin,
but not F-actin, redistribution via endocytosis. Further,
this study demonstrates that IL-2 therapy-induced EC
barrier dysfunction can be detected by using a novel
ex vivo transwell model that measures increases in dex-
tran fluxes across primary human pulmonary micro-
vascular ECs. We believe that such a primary human
pulmonary microvascular EC model can be used as an
ex vivo methodology for future research in VLS. In our
study, similar findings were made using both in vitro as-
says utilizing defined doses of recombinant IL-2 and
ex vivo assays where ECs were exposed to sera from pa-
tients treated with HDIL2, suggesting that a similar
mechanism may be operative in vivo.
Conclusions
VLS is a major challenge to the clinical management of
patients treated with HDIL2 and other related cytokines.
A better understanding of the mechanisms of VLS may
provide new therapeutic targets for ameliorating VLS
while not interfering in the immune-mediated activity of
IL-2, which is important for the therapeutic effectiveness
of the cytokine treatment. In this report we identified
CD144 (VE-cadherin) redistribution as a mechanism of
IL-2-associated VLS, which differs from TNF-α-associated
changes in vascular permeability. Other soluble and cellu-
lar mediators may also contribute to changes in vascular
permeability and the transwell model may be ideal for fur-
ther studies aimed at defining the mechanism of IL-2-
related vascular leak syndrome.
Additional files
Additional file 1: Figure S1. Change in dextran flux under varying IL-2
doses. ECs were treated (as described for Figure 1D) with 100. 1000, or
10000 IU/ml IL-2 or without [Vehicle: PBS], and the flux of dextran across
ECs was measured 24 hours after treatment. Data are presented as mean
fold change in dextran flux (IL-2-treated/Vehicle) + S.E.M. and representative
of three experiments with similar results. *p < 0.05 examined using ANOVA.
Additional file 2: Figure S2. Serum IL-2 induces CD144 (VE-cadherin)
distribution. A-D) Primary human pulmonary microvascular ECs were
treated (as described for Figure 3) with paired pre- or post-IL-2 serum
from patient 3 (A) and patient 4 (C) and the effect on the distribution of
CD144 (VE-cadherin) and F-actin was examined using confocal microscopy.
(B) and (D) show quantification of data from (A) and (C), respectively, using
imagej64 software (NIH). VE-cadherin and F-actin intracellular redistribution
(i.e., intracellular intensity in arbitrary units) is shown. Data represent two
independent experiments.
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